Aktuellt
SENASTE
Cantargia posted its Q4 numbers this morning with an operating loss of SEK 105.8m, 4% more negative vs our estimates at SEK -102m. The R&D costs totalled SEK 101.8m, 4% more negative than we expected and is up about 91% from last year which is primarily attributable to the main project CAN04 but also the expansion of clinical programmes. The company has not changed its expected cash spending ahead and the current cash balance at SEK 247m should last for another 18 months.
LÄS MER
